Working… Menu

B2-Adrenergic Receptor Polymorphisms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00279786
Recruitment Status : Completed
First Posted : January 20, 2006
Last Update Posted : July 28, 2009
Information provided by:
Connecticut Children's Medical Center

Brief Summary:

Beta(2)-adrenergic receptor (BAR) agonists are the most important group of drugs used in the treatment of asthma. In children unresponsive to inhaled BAR agonist therapy, higher dose systemic BAR agonist therapy is frequently the next step in treatment. Despite the widespread use of intravenous BAR agonist therapy for pediatric status asthmaticus, there is controversy regarding the efficacy of this therapy. A number of studies have established that genetic variations of the BAR have important effects in modulating responses to BAR agonist therapy for asthma. In particular, changes in amino acid position 16 of the BAR gene are thought to be the most functionally important. Patients encoded for two glycine amino acids, rather than arginine, at this position appear to have more severe asthma and to respond differently to acute BAR agonist therapy.

Our hypothesis is that genotypic differences may contribute to poor response to acute BAR agonist treatment. We propose to conduct a prospective observational study to determine the influence of a patient's BAR genotype on the response to acute BAR agonist therapy.

Our specific hypothesis is that children with genetic polymorphisms of the gene encoding the BAR will have a decreased response to acute high-dose continuous BAR therapy (both inhaled and intravenous) compared to other children.

Our primary outcome is ICU length of stay. Secondary outcomes are

  1. to assess the rate of improvement in clinical asthma score based on genotype, and
  2. to attempt to correlate asthma phenotype with genotype by comparing demographic data and hospital course.

Condition or disease Intervention/treatment
Status Asthmaticus Procedure: Blood draw

Detailed Description:
This study has both a prospective and a retrospective arm. In the retrospective arm, patients with a history of admission to the ICU with a severe asthma exacerbation are contacted by phone and mail and DNA samples are obtained via saliva. In the prospective arm, patients admitted to the ICU are contacted prospectively and DNA is obtained either via saliva or blood.

Layout table for study information
Study Type : Observational
Actual Enrollment : 126 participants
Observational Model: Cohort
Official Title: B2-Adrenergic Receptor Polymorphisms: Implications For The Treatment Of Status Asthmaticus In Children
Study Start Date : December 2005
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Intervention Details:
  • Procedure: Blood draw
    blood drawn
    Other Name: genotyping of ß2-AR at position 16 and 27.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Children admitted to the ICU with severe asthma exacerbations

Inclusion Criteria:

  • (1) Admission to the CCMC PICU with a primary admission diagnosis of status asthmaticus. (2) Age between 2 years and 18 years.

Exclusion Criteria:

  • Pre-existing chronic disease (other than asthma)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00279786

Layout table for location information
United States, Connecticut
CT Children's Medical Center
Hartford, Connecticut, United States, 06106
Sponsors and Collaborators
Connecticut Children's Medical Center
Layout table for investigator information
Principal Investigator: Christopher Carroll, MD CT Children's Medical Center

Layout table for additonal information
Responsible Party: Christopher Carroll, MD, Connecticut Children's Medical Center Identifier: NCT00279786     History of Changes
Other Study ID Numbers: 06-001
First Posted: January 20, 2006    Key Record Dates
Last Update Posted: July 28, 2009
Last Verified: July 2009
Keywords provided by Connecticut Children's Medical Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Status Asthmaticus
Bronchial Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs